These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 28700465)
1. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials. Zheng J; Song W Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465 [TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178 [TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Morgan RD; O'Callaghan JM; Knight SR; Morris PJ Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659 [TBL] [Abstract][Full Text] [Related]
5. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin. Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622 [TBL] [Abstract][Full Text] [Related]
6. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365 [TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review. Zhang X; Huang H; Han S; Fu S; Wang L Transpl Immunol; 2012 Oct; 27(2-3):63-8. PubMed ID: 22960043 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis. Hao WJ; Zong HT; Cui YS; Zhang Y Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005 [TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of preoperative induction therapy using a single high dose ATG-F in renal transplantation: a meta-analysis of randomized controlled trials]. Yin H; Xu Y; Zhang Q; Xue WR; Zhang ZJ; Zeng S; Hu XP Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1773-7. PubMed ID: 27356647 [TBL] [Abstract][Full Text] [Related]
10. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Liu Y; Zhou P; Han M; Xue CB; Hu XP; Li C Transplant Proc; 2010 Jun; 42(5):1667-70. PubMed ID: 20620496 [TBL] [Abstract][Full Text] [Related]
11. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation. Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073 [TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction . Descourouez JL; Jorgenson MR; Parajuli S; Mandelbrot DA; Leverson GE; Odorico JS; Redfield RR Clin Nephrol; 2020 Feb; 93(2):77-84. PubMed ID: 31670651 [TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Lü TM; Yang SL; Wu WZ; Tan JM Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554 [TBL] [Abstract][Full Text] [Related]